Sarepta and the distance between hope and proof

A boy rises from the floor. In a clinic, that ordinary movement becomes a timed test, a number, and perhaps evidence that a medicine is helping. In a biotechnology company, it can become the difference between an encouraging biological result and a convincing treatment. Sarepta Therapeutics has built a business inside that distance.

• Two approaches: skip a troublesome RNA segment, or deliver instructions for a shortened muscle protein.
• Four marketed medicines: three exon-skipping drugs and the gene therapy Elevidys.
• The unresolved work: demonstrate benefit, select patients carefully and manage serious risks.

Duchenne muscular dystrophy progressively damages muscle. Mutations disrupt dystrophin, a protein that helps keep muscle cells intact. Walking, breathing and heart function can all be affected. The appeal of genetic medicine is easy to understand: intervene closer to the biological fault. The difficulty is that a plausible mechanism does not automatically produce a measurable improvement in a child’s life.

A workaround written in three numbers

Sarepta’s first commercial answer was exon skipping. Its medicines influence how cells process the RNA instructions used to make dystrophin. For particular mutations, skipping a selected exon can restore the reading frame, allowing production of a shortened protein. Think of it as an alternate reading route through damaged instructions.

Exondys 51 arrived in 2016, Vyondys 53 in 2019 and Amondys 45 in 2021. The numbers identify the targeted exons. Each medicine requires an appropriate mutation and weekly intravenous infusions. A Duchenne diagnosis alone does not establish eligibility. These are separate, genetically defined patient groups, rather than three competing flavors of the same prescription.

All three entered through accelerated approval, based on increased dystrophin production. Confirming clinical benefit remains a separate assignment. In 2026, Sarepta reported that ESSENCE, the confirmatory trial for Amondys and Vyondys, missed its primary endpoint. FDA subsequently accepted applications seeking traditional approval, with a February 28, 2027 target decision date. Acceptance starts a review; it does not settle the result.

The infusion that changed the argument

Elevidys takes another route. A viral vector delivers genetic instructions for micro-dystrophin, a shortened version of the protein. It does not repair the original gene. Initially approved in 2023, it brought a single-infusion proposition into a disease whose care otherwise unfolds over years.

The pivotal EMBARK trial then missed its primary motor-function endpoint. Sarepta emphasized favorable secondary measures, including timed tests. FDA granted traditional approval for ambulatory patients aged four and older in 2024 and accelerated approval for non-ambulatory patients. The sequence matters: a missed endpoint is a specific result, and a regulatory decision considers an evidence package. Neither should disappear from the story.

“Science, and the relentless search for answers, is the basis of genetic medicine.”

Michael Severino, Sarepta CEO

Then came fatal acute liver failure in two non-ambulatory patients. In July 2025, FDA requested a shipment suspension. Sarepta initially declined, then paused shipments; FDA later recommended lifting the voluntary hold for ambulatory patients. By November, the approved label carried a boxed warning and excluded non-ambulatory use. Serious liver risk remains relevant to the patients still eligible.

The practical boundary is precise: current U.S. approval covers ambulatory patients aged four and older with a confirmed DMD mutation, subject to contraindications and other restrictions. Some mutations exclude treatment; liver status and immunity also matter. A specialist’s assessment, corticosteroids and close monitoring are part of delivery. Calling it a one-time treatment can obscure the months of care surrounding the infusion.

The business beneath the headline drug

Sarepta sells prescription medicines through a system of specialists, treatment centers, distributors and payers. Families use the treatments; insurers and health systems help determine access. Its SareptAssist program supports the treatment journey and insurance navigation. Scientific eligibility and financial access are different gates, and both have to open.

The commercial picture is more complicated than the gene therapy headlines suggest. Total 2025 revenue reached $2.198 billion, including collaboration and other revenue. Net product revenue was $1.864 billion. In the second quarter of 2026, the three RNA medicines generated $230.6 million, versus $98.1 million for Elevidys. The recurring infusion business supplied most product revenue that quarter.

The price of changing direction was concrete. In July 2025, Sarepta announced roughly 500 job cuts and a plan targeting about $400 million in annual savings. It prioritized siRNA programs while pausing several other projects. The Arrowhead agreement had already supplied a route into that science: $500 million upfront plus a $325 million equity investment, before additional obligations.

A company old enough to change its mind

James Summerton founded the business as AntiVirals in 1980. It went public in 1997 and adopted the Sarepta name in 2012. Thirty-six years separated incorporation from its first Duchenne drug. That history makes the current portfolio look less like a single invention than an accumulation of chemistry, clinical development, partnerships and expensive revisions.

One useful move other businesses can study is the division of labor. Roche received overseas commercialization rights to Elevidys through an agreement announced in 2019; the partners agreed to share global development costs equally. Sarepta retained development and manufacturing responsibilities. The arrangement bought reach and shared expense without requiring Sarepta to build every commercial capability itself.

Its competitive position remains specific. NS Pharma offers another exon-53-skipping drug, Viltepso. Duvyzat addresses Duchenne through a different mechanism, alongside a broader care landscape that includes corticosteroids. These options have different indications and roles. A list of brand names cannot substitute for a treatment plan.

In October 2026, Sarepta reported new preclinical evidence that investigational SRP-1003 reduced disease-associated RNA inside the cell nucleus in DM1 models. That is a laboratory finding, not proof of human benefit. The useful habit to copy is to keep those statements separate. For Sarepta, the next persuasive number must connect a molecular change to something a patient can actually do.